The global impetigo drug market is anticipated to grow at a significant CAGR of 7.1% during the forecast period. One of the major factors that are augmenting the growth of the impetigo drug market rising mode of transmission of impetigo diseases. Impetigo is a highly infectious skin condition that primarily affects toddlers and new born. The bacteria streptococcus or staphylococcus aureus produce this form of infection. This infection causes red sores or bumps blisters on the patient's face, especially around the nose, feet, hands, and mouth. This condition affects generally those who participate in sports that require close physical contacts, such as wrestling and rugby. Furthermore, topical treatments can assist to alleviate the disease's symptoms. As a result, producers are working on more effective antibiotics for skin infections. For instance, in May 2021, Teva Pharmaceutical Industries Ltd., had introduced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets in order to treat a variety of bacterial infections, along with preventing initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.

Impact of COVID-19 Pandemic on Global Impetigo Drug Market

The COVID-19 pandemic had impacted the global impetigo drug market significantly owning to the lockdown in most nations to control the spread of the virus. It affected the overall demand for impetigo drugs in the market. Additionally, due to the COVID-19 pandemic, the supply chain had also been disrupted as a result of precautionary actions implemented by governments in various countries which in turn, adversely impacted the growth of the market.  

Segmental Outlook 

The global impetigo drug market is segmented based on drug class and distribution channel. Based on the drug class, the market is sub-segmented into fusidane, quinolones, sulfonamide, and tetracycline. Based on the distribution channel, the market is sub-segmented into online and offline. 

Global Impetigo Drug Market Share by Drug Class, 2021 (%)

The Fusidane Segment Holds the Prominent Share in the Global Impetigo Drug Market

The Fusidane segment holds the prominent market share and is anticipated to grow significantly during the forecast period in the global impetigo drug market in the drug class segment. Fusidic acid is used to treat skin infections caused by bacteria known as staphylococci. Impetigo, infected cuts and grazes, and infected dermatitis are examples of such infections. It works by preventing the infection-causing bacteria from multiplying. Sodium fusidate is a salt of fusidic acid that functions in the same way that fusidic acid does. Antibacterial medicines such as fusidic acid cream and sodium fusidate ointment frequently clear skin infections fast, especially when the infection is limited to a small area. Due to the increased adoption of topical treatment due to more effective results compared to oral antibiotics with minimal adverse side effects, the fusidane segment has substantial growth. 

Regional Outlooks

The global impetigo drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.

Global Impetigo Drug Market Growth, by Region 2022-2028

The Asia-Pacific Region Expected to Hold Considerable Share in the Global Impetigo Drug Market

The Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the impetigo drug market. The presence of emerging countries such as China, Japan, India, and South Korea are taking big initiatives to fuel up the overall impetigo drug market. Due to the developing healthcare infrastructure and increased awareness of skin infections, Asia pacific is the most significant market for impetigo. Furthermore, the high prevalence of impetigo infections in hot and humid places accounts for increased infections in the Asia Pacific, resulting in market expansion.

Market Players Outlook

The major companies serving the global impetigo drug market include Cutanea Life Sciences, GlaxoSmithKline plc., LEO Pharma A/S, Medimetriks Pharmaceuticals Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022. Pfizer got approval for CIBINQO (abrocitinib) which is an oral inhibitor for the treatment of patients suffering from moderate to severe dermatitis. CIBINQO will be a significant new oral option for those who have not yet found relief. CIBINQO showed good efficacy in clearing skin, reducing itching, and managing the intensity and extent of eczema, with a benefit-risk profile that supports its usage in the FDA-approved patient population.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global impetigo drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.